uniQure N.V. Ordinary Shares vs Trade Desk Inc — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Trade Desk Inc trades at $12.12 (market cap $5.75B). The key difference: Trade Desk Inc is far larger — about 3.9× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Trade Desk Inc for 73 Days on average.
| QURE | TTD | |
|---|---|---|
Market Cap | $1.48B | $5.75B |
Volume | 2,488,780 | 15,249,283 |
Sector | Health | Media |
52-Week High | $70.59 | $54.13 |
52-Week Low | $9.03 | $11.92 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $728.62M | $4.70B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The Trade Desk (TTD) trades at $12.18, down 68% year-to-date amid slowing revenue growth and increased competition. Technical indicators show bearish momentum with mixed earnings performance, beating estimates in Q2 but missing in Q1. The company maintains strong profitability margins (76.9% gross margin) but faces headwinds from Amazon and other tech giants expanding into ad-tech. Recent workforce reductions and downward revenue guidance reflect operational challenges.
Despite current pressures, TTD maintains leadership in programmatic advertising with solid cash flow generation. Analyst consensus suggests 20% upside to the $14.68 price target, though competitive threats and slowing growth present significant risks. The stock's valuation appears reasonable with P/E of 0.14 and P/S of 0.02, but investors should weigh the company's ability to defend its market position against larger competitors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →